SalaryGuide
AboutPricingFor Employers

Marketing jobs

3 marketing jobs

Diasorin logo
2 months ago

Senior Product Marketing Manager

Diasorin

Austin, TX (On-site)Full time
Diasorin logo
3 months ago

Director, Marketing Communications

Diasorin

Austin, TX (On-site)Full time
Diasorin logo
4 months ago

Global Marketing Copywriter

Diasorin

Austin, TX (On-site)Full time

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

3 jobs
Diasorin logo

Senior Product Marketing Manager

Diasorin

Austin, TX (On-site)

In-houseFull-timeSenior level10+ years exp.
2 months ago
Diasorin logo

Director, Marketing Communications

Diasorin

Austin, TX (On-site)

In-houseFull-timeDirector/executive
3 months ago
Diasorin logo

Global Marketing Copywriter

Diasorin

Austin, TX (On-site)

In-houseFull-timeMid level3+ years exp.
4 months ago
Diasorin logo
Diasorin

Senior Product Marketing Manager

Austin, TX (On-site)

Salary Not AvailableSenior Level10+ years expFull time

Posted 2 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the LTG go-to-market narrative and strategic GTM program to accelerate partner adoption and revenue.

  • Own master messaging architectures that translate complex science into customer value across campaigns, enablement, and sales plays.
  • Lead segmentation and adoption frameworks (personas, TAM/SAM/SOM, buying criteria) to guide targeting and resource allocation.
  • Architect integrated GTM programs (SEM, content, email, social, partner marketing) and establish KPI dashboards for MQL→SQL quality and ROI.

Job Description

Responsibilities

  • The Sr Product Marketing Manager will own the Luminex Licensed Technology Group's go-to-market strategy and technical narrative to accelerate partner success and adoption.
  • Lead market strategy, messaging, campaigns, and sales enablement—translating complex technology into compelling value propositions and orchestrating integrated programs that drive pipeline and revenue outcomes.
  • Strategic Marketing & Market Insights: Inform LTG market strategy: synthesize market research, VOC, and commercial insights into clear recommendations that shape product roadmaps, and GTM priorities.
  • Build and operationalize segmentation & adoption frameworks (personas, TAM/SAM/SOM, buying criteria) to guide targeting, resource allocation, and commercialization plans.
  • Anticipate market shifts (competitive, regulatory, technology trends) and advise leadership on positioning, investment, and partner strategy.
  • Co-develop with strategic partners to validate use cases, inform new offerings, and de-risk adoption.
  • Messaging & Positioning: Own master messaging architectures that translate complex scientific and workflow concepts into differentiated, customer centric value propositions. centric value propositions.
  • Lead global positioning strategies aligned to personas, research/clinical workflows, and regional priorities—ensuring consistency with room for localization.
  • Partner with R&D and Product to convert performance data and validation evidence into compelling, evidence-backed stories.
  • Advance Luminex’s innovation narrative to reinforce platform advantages and brand leadership.
  • Campaigns & Demand Generation: Architect integrated GTM programs (SEM, content, email nurture, social, partner co-marketing) to drive awareness, pipeline, and adoption across partner channels.
  • Map and optimize the full journey—from discovery to enablement to expansion—reducing friction and improving conversion, engagement, and retention.
  • Lead launch excellence for new products, assays, and updates; align marcom, PM, BD, and regions on objectives, timelines, and success metrics.
  • Establish KPI dashboards to track MQL→SQL quality, partner engagement, pipeline contribution, and ROI; iterate with data.
  • Sales Enablement & Collateral: Equip global commercial teams and partners with strategic tools (battle cards, objection handling, value frameworks, case studies, executive decks, web site content) tied to clear plays.
  • Deliver training programs that elevate field proficiency in product value, use cases, workflows, and competitive differentiation.
  • Govern content standards and reuse to ensure accuracy, scientific integrity, and brand consistency across collateral.
  • Align sales enablement tools and training with key revenue goals—acquiring new customers, expanding existing accounts, and driving broader adoption across partner portfolios.
  • Events & Thought Leadership: Set tradeshow strategy to maximize brand visibility, partner activation, and qualified lead capture with clear pre/during/post plans.
  • Cultivate KOLs and customer champions to support early adoption, validation, publications, and co-marketing .

Requirements

  • Bachelor's Degree Bachelor’s in Biology/Chemistry/Engineering (MBA preferred) with 10+ years in product marketing, product management, or business development within Life Sciences, Pharma, Analytical Instrumentation, or Diagnostics required
  • 10+ Years Deep understanding of Life Science Research, drug development, diagnostics/IVD markets, assays, and analytical workflows; proven record shaping product and GTM strategy required
  • Fluency in Salesforce + marketing automation (Marketo/Pardot) and analytics (Google Analytics); excellent technical writing, communication, and cross-functional leadership. (High proficiency)
  • Bias for impact: adept at managing multiple priorities, meeting tight deadlines, and delivering measurable commercial outcomes. (High proficiency)
  • Collaborative team player with a track record of engaging cross-functional stakeholders. (High proficiency)

Nice to Have

  • MBA preferred

Benefits

  • Our people are passionate about what they do, the product they sell, and the customers they serve.
  • If you're looking for an opportunity to be a part of a work family that values collaboration, innovation and dedication, we're the right company for you.
  • Diasorin is committed to building a workplace where people feel empowered to contribute ideas, take ownership, and grow their careers.
  • We believe diverse perspectives strengthen innovation and help us deliver meaningful impact for patients and customers worldwide.
Diasorin logo

Diasorin

Headquartered in Italy and listed on the Italian Stock Exchange within the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and, since 2021, has been active in the Life Science business. For over 50 years, the Company has been developing, producing, and marketing reagent kits used by diagnostic laboratories worldwide.The Group operates across five continents through 35 companies, 4 branches, 10 manufacturing facilities, and 9 research and development centers. Our extensive diagnostic testing and life science offering, continuously enhanced through significant investments in research, positions Diasorin as the player with the broadest range of specialty tests available in the diagnostic market, identifying the Group as “The Diagnostic Specialist.”With a team of over 3,200 employees worldwide, including more than 400 researchers, we are committed to improving healthcare and enhancing people's quality of life. We value diversity, skills, and talent as key drivers of innovation and excellence, fostering an inclusive work environment that evolves alongside the ever-changing landscape of global healthcare.

Founded in 1968
Salasco, Piedmont, ITA
2.6K employees (92 in marketing)
www.diasorin.com

Traffic Signals

Monthly Visitors
77K
Traffic Source Mix
Search
43%
Direct
40.6%
Referral
8.3%
Social
6.7%
Paid
1.3%

Headcount Trend

Current headcount: ~2.6K

Marketing Team

Marketing Team Size
86 (3% of company)

Recent News

Analisi prezzi azioni italiane: Diasorin, Leonardo, Eni
Oct 13, 2025 • FXEmpire
Diasorin trasforma il Service globale: verso un ecosistema intelligente e predittivo
Oct 10, 2025 • cmimagazine.it
Diasorin, perché Deutsche Bank taglia il target price in attesa della trimestrale. Le stime
Oct 8, 2025 • Milano Finanza
Piazza Affari: andamento sostenuto per DiaSorin
Oct 1, 2025 • Teleborsa
Diasorin trasforma il Service con Salesforce
Sep 30, 2025 • TecnoMedicina
Diasorin lancia un nuovo test. Azione sui minimi del 2025 in borsa: ecco perché il mercato sbaglia
Sep 19, 2025 • Milano Finanza
Piazza Affari: andamento sostenuto per DiaSorin
Sep 17, 2025 • Teleborsa
UBS promuove DiaSorin a "buy" e alza il target a €98 sulle prospettive di crescita al 2026
Sep 17, 2025 • Investing.com
Diasorin sale con upgrade Ubs a ‘Buy’ e migliore target prezzo
Sep 17, 2025 • Il Sole 24 ORE
Azioni Diasorin sono da comprare? UBS lancia view bullish, trader ci credono
Sep 17, 2025 • Borsainside
Milano la sola ribassista; DiaSorin best performer
Sep 17, 2025 • MarketScreener Italia
Diasorin - Prezzo sui minimi dal gennaio 2019
Sep 15, 2025 • Websim
Diasorin e Interpump entrano nell'indice MIB ESG
Sep 12, 2025 • Borsa Italiana
Diasorin e Interpump entrano nell'indice MIB ESG
Sep 12, 2025 • Teleborsa
Mad for Science: Al Via le Candidature per il Concorso della Fondazione Diasorin Ets sul Tema Risorse Naturali e Salute
Sep 11, 2025 • EduNews24
Piazza Affari: movimento negativo per DiaSorin
Sep 4, 2025 • La Stampa
Diasorin, prese di beneficio alimentate da JP Morgan
Aug 27, 2025 • orafinanza.it
Diasorin: Ombre sulla Crescita e sulla Valutazione - Scopri Subito i Motivi
Aug 27, 2025 • Investing.com
Azioni Diasorin: crollo dopo boom di ieri! Cosa sta succedendo in borsa?
Aug 27, 2025 • Meteofinanza.com
Diasorin colpita dalle prese di beneficio e dal giudizio "underweight" di JPMorgan
Aug 27, 2025 • Il Sole 24 ORE
DiaSorin vola in Borsa dopo promozione a Overweight da Morgan Stanley
Aug 26, 2025 • la Repubblica
DiaSorin vola in Borsa dopo promozione a Overweight da Morgan Stanley
Aug 26, 2025 • Teleborsa
Borsa Milano in calo con banche su incertezza politica Francia, bene Diasorin
Aug 26, 2025 • Yahoo Finanza
Diasorin, Morgan Stanley alza target price. Possibile uscita dal FTSE MIB
Aug 26, 2025 • orafinanza.it
Diasorin in rally in borsa: perché Morgan Stanley promuove l’azione
Aug 26, 2025 • Milano Finanza
Rally delle azioni Diasorin: l’upgrade di Morgan Stanley spinge il titolo in Borsa
Aug 26, 2025 • Benzinga Italia
Azioni Diasorin da sovrappesare? La dritta che fa impazzire i trader
Aug 26, 2025 • Borsainside
Azioni Diasorin: per gli analisti di Rbc Capital il target price è 105 euro, cosa fare
Aug 26, 2025 • Borsa&Finanza
Spunti su Diasorin: occasione d’acquisto secondo Rbc
Aug 14, 2025 • orafinanza.it
Azioni Diasorin: valore giusto è 105 euro? Da RBC assist potente per comprare
Aug 14, 2025 • Borsainside
Azioni Diasorin: nuovi minimi in arrivo dopo i dati semestrali?
Aug 4, 2025 • Investire.biz
Diasorin, ricavi in crescita a 619 milioni e guidance confermata
Aug 1, 2025 • la Repubblica
Diasorin - Transizione e cautela: prospettive di crescita
Aug 1, 2025 • Websim
Diasorin, più dividendi per i Denegri dalla cassaforte Finde
Aug 1, 2025 • Milano Finanza
Diasorin: impatto stimato dazi su marginalita' 2025 "non significativo"
Jul 31, 2025 • Il Sole 24 ORE
Diasorin, ricavi e margini in crescita nel semestre. Confermata guidance 2025
Jul 31, 2025 • la Repubblica
Diasorin, nel primo semestre crescono ricavi e utile netto. Sprint delle vendite in Nord America
Jul 31, 2025 • Milano Finanza
Diasorin - Richiesta di autorizzazione FDA per LIAISON NES®
Jul 2, 2025 • Websim
Diasorin: il super test Liaison Nes attende il via libera della Fda
Jul 2, 2025 • Milano Finanza
Diasorin: perché è importante l’ok della Fda al pannello per la diagnosi delle infezioni del sangue, il Liaison Plex
Jun 9, 2025 • Milano Finanza
Diasorin in rialzo dopo l'ok Fda al pannello su diagnosi di infezioni del sangue
Jun 9, 2025 • Il Sole 24 ORE
Louder (part of SG Company) consolida la sua presenza nel mercato della diagnostica internazionale: firmata per Diasorin l’area espositiva a ESCMID Global 2025
May 12, 2025 • mediakey.it
Diasorin: nel primo trimestre fatturato in crescita dell’8% e margine EBITDA al 34%
May 6, 2025 • TecnoMedicina
Dividendo Diasorin 2025: ammontare e stacco
May 2, 2025 • orafinanza.it
Diasorin, la trimestrale in arrivo scalda le previsioni del mercato
Apr 29, 2025 • Morningstar Canada
DiaSorin, ok da soci a bilancio e dividendo. Eletto nuovo CdA
Apr 28, 2025 • la Repubblica
Azioni Diasorin: il pharma limita i danni in Borsa dopo i dazi Usa
Apr 14, 2025 • Borsa&Finanza
Il pharma italiano limita i danni in borsa dopo i dazi, le prospettive di Diasorin e Recordati per gli analisti
Apr 7, 2025 • Milano Finanza
Borse oggi in diretta | Il Ftse Mib travolto dai dazi: -6,5%. Crollano banche e Leonardo, tra le blue chip resiste solo Diasorin
Apr 4, 2025 • Milano Finanza
Diasorin ottiene l’annullamento della sanzione amministrativa di Consob: tutti i legali
Mar 17, 2025 • Legalcommunity
Diasorin: approvati i risultati dell’esercizio 2024
Mar 14, 2025 • TecnoMedicina
Diasorin, nel 2024 ricavi e utili in netta crescita. Proposto dividendo a 1,2 euro
Mar 14, 2025 • la Repubblica
Diasorin: utile netto 2024 a 187 mln (+18%), ricavi +3% e cedola di 1,2 euro
Mar 14, 2025 • Il Sole 24 ORE
Diasorin, nel 2024 utile in crescita del 18%. Per i soci cedola di 1,2 euro per azione, ma il titolo frena
Mar 14, 2025 • Milano Finanza
Cosa aspettarsi dalla trimestrale Diasorin dopo la recente volatilità?
Mar 10, 2025 • Morningstar Canada
DiaSorin, promozione a Buy da Stifel con aumento target price
Feb 12, 2025 • Teleborsa
Fondazione Diasorin accreditata dal ministero dell'Istruzione e del merito come ente formatore
Feb 6, 2025 • AboutPharma
«Per Diasorin le valutazioni sono attraenti»
Jan 22, 2025 • Il Sole 24 ORE
Azioni Diasorin, calendario finanziario 2025: trimestrali, assemblea azionisti
Jan 21, 2025 • orafinanza.it
DiaSorin: il calendario e date stacco dividendi 2025
Jan 9, 2025 • Investire.biz
Diasorin in calo, Ubs rivede la valutazione da "buy" a "neutral"
Nov 26, 2024 • Il Sole 24 ORE